126 related articles for article (PubMed ID: 576725)
21. Bomocriptine treatment of patients with acromegaly resistant to conventional therapy.
Pelkonen R; Ylikahri R; Karonen SL
Clin Endocrinol (Oxf); 1980 Mar; 12(3):219-24. PubMed ID: 6993053
[TBL] [Abstract][Full Text] [Related]
22. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
23. Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly.
Demura R; Yamaguchi H; Demura H; Shizume K
Endocrinol Jpn; 1978 Aug; 25(4):355-9. PubMed ID: 710371
[TBL] [Abstract][Full Text] [Related]
24. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
25. Long-term treatment of acromegaly with bromocriptine.
Wass JA; Thorner MO; Morris DV; Rees LH; Mason AS; Jones AE; Besser GM
Br Med J; 1977 Apr; 1(6065):875-8. PubMed ID: 576843
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment of acromegaly with bromocriptine.
Eskildsen PG; Svendsen PA; Vang L; Nerup J
Acta Endocrinol (Copenh); 1978 Apr; 87(4):687-700. PubMed ID: 417539
[TBL] [Abstract][Full Text] [Related]
27. Chronic bromocriptine treatment and glucose intolerance in acromegaly.
Popović V; Micić D; Nesović M; Djordjević P; Mićić J; Djurić DS
Exp Clin Endocrinol; 1985 Jun; 85(3):351-7. PubMed ID: 3899685
[TBL] [Abstract][Full Text] [Related]
28. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
[TBL] [Abstract][Full Text] [Related]
29. The effect of bromocriptine on insulin secretion and glucose tolerance in patients with acromegaly.
Feek CM; Bevan JS; Taylor S; Brown NS; Baird JD
Clin Endocrinol (Oxf); 1981 Nov; 15(5):473-8. PubMed ID: 7035013
[TBL] [Abstract][Full Text] [Related]
30. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of acromegaly with bromocriptine.
Thorner MO; Besser GM
Postgrad Med J; 1976; 52suppl 1():71-4. PubMed ID: 959128
[No Abstract] [Full Text] [Related]
32. The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study.
Eskildsen PC; Hommel E; Buchhave J
Clin Endocrinol (Oxf); 1985 Feb; 22(2):189-200. PubMed ID: 3886207
[TBL] [Abstract][Full Text] [Related]
33. Long-term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration.
Benker G; Zäh W; Hackenberg K; Hamburger B; Günnewig H; Reinwein D
Horm Metab Res; 1976 Jul; 8(4):291-5. PubMed ID: 182633
[TBL] [Abstract][Full Text] [Related]
34. Serum growth hormone and ultrastructural studies of adenohypophysial tissue in bromocriptine treated acromegalic patients.
Fanghanel-S G; Larraza O; Arauco R; Esquivel R; Martinez Campos A; Valverde-R C
Clin Endocrinol (Oxf); 1978 Oct; 9(4):289-96. PubMed ID: 102468
[TBL] [Abstract][Full Text] [Related]
35. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
36. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
[TBL] [Abstract][Full Text] [Related]
37. Depot-bromocriptine treatment for prolactinomas and acromegaly.
Grossman A; Ross R; Wass JA; Besser GM
Clin Endocrinol (Oxf); 1986 Feb; 24(2):231-8. PubMed ID: 3708874
[TBL] [Abstract][Full Text] [Related]
38. Treatment of acromegaly by trans-sphenoidal operation, 90-yttrium implantation and bromocriptine: results in 230 patients.
Quabbe HJ
Clin Endocrinol (Oxf); 1982 Feb; 16(2):107-19. PubMed ID: 7067156
[TBL] [Abstract][Full Text] [Related]
39. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
[TBL] [Abstract][Full Text] [Related]
40. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans.
Liuzzi A; Chiodini PG; Oppizzi G; Botalla L; Verde G; De Stefano L; Colussi G; Gräf KJ; Horowski R
J Clin Endocrinol Metab; 1978 Feb; 46(2):196-202. PubMed ID: 108287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
